GT Biopharma Statistics
Total Valuation
GT Biopharma has a market cap or net worth of $6.84 million. The enterprise value is $420,043.
| Market Cap | 6.84M |
| Enterprise Value | 420,043 |
Important Dates
The last earnings date was Thursday, November 14, 2024, after market close.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
GT Biopharma has 2.23 million shares outstanding. The number of shares has increased by 31.99% in one year.
| Current Share Class | 2.23M |
| Shares Outstanding | 2.23M |
| Shares Change (YoY) | +31.99% |
| Shares Change (QoQ) | +30.51% |
| Owned by Insiders (%) | 7.14% |
| Owned by Institutions (%) | 65.40% |
| Float | 1.67M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.26 |
| P/TBV Ratio | 3.26 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.45
| Current Ratio | 1.45 |
| Quick Ratio | 1.38 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -204.08% and return on invested capital (ROIC) is -141.15%.
| Return on Equity (ROE) | -204.08% |
| Return on Assets (ROA) | -75.14% |
| Return on Capital (ROIC) | -141.15% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$6.17M |
| Employee Count | 2 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -55.65% in the last 52 weeks. The beta is 0.57, so GT Biopharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.57 |
| 52-Week Price Change | -55.65% |
| 50-Day Moving Average | 2.56 |
| 200-Day Moving Average | 3.15 |
| Relative Strength Index (RSI) | 55.01 |
| Average Volume (20 Days) | 21,827 |
Short Selling Information
The latest short interest is 17,725, so 0.79% of the outstanding shares have been sold short.
| Short Interest | 17,725 |
| Short Previous Month | 10,375 |
| Short % of Shares Out | 0.79% |
| Short % of Float | 1.06% |
| Short Ratio (days to cover) | 0.71 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -13.77M |
| Pretax Income | -9.64M |
| Net Income | -12.35M |
| EBITDA | n/a |
| EBIT | -13.77M |
| Earnings Per Share (EPS) | -$7.36 |
Balance Sheet
| Cash & Cash Equivalents | 6.42M |
| Total Debt | n/a |
| Net Cash | 6.42M |
| Net Cash Per Share | $2.87 |
| Equity (Book Value) | 2.10M |
| Book Value Per Share | 0.94 |
| Working Capital | 2.10M |
Cash Flow
| Operating Cash Flow | -12.48M |
| Capital Expenditures | n/a |
| Free Cash Flow | -12.48M |
| FCF Per Share | -$5.59 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
GT Biopharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -31.99% |
| Shareholder Yield | -31.99% |
| Earnings Yield | -180.62% |
| FCF Yield | -182.58% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on February 5, 2024. It was a reverse split with a ratio of 0.0333333:1.
| Last Split Date | Feb 5, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.0333333:1 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |